Ireland
--:--IST
Priya Life Science Rare disease register
European Union · EMA · Rare diseases

EU orphan designations

Every medicine the European Commission has designated as an orphan medicine for a rare disease, on the EMA's recommendation, with its current status.

Source: European Medicines Agency, orphan designations data (reproduced with acknowledgement of the source). Synced 10 Nov 2026
3,310Orphan designations listed
2,201Currently active
114Designated in the last 12 months
1,073Withdrawn or expired
01

Matching designations

20 matches
SubstanceIntended useStatusDesignated
autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19
EU/3/24/3011
Treatment of myasthenia gravis Active (positive) 20 Feb 2025
autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti-CD19 CD28/CD3-zeta chimer…
EU/3/20/2344 · now authorised as Tecartus
Treatment of acute lymphoblastic leukaemia Active (positive) 19 Oct 2020
autologous T cells transduced with lentiviral vector containing a tandem chimeric antigen receptor directed against CD20 and CD19
EU/3/20/2327
2 clinical trials →
Treatment of diffuse large B-cell lymphoma Active (positive) 21 Aug 2020
autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti CD19 CD28/CD3-zeta chimer…
EU/3/19/2220 · now authorised as Tecartus
Treatment of mantle cell lymphoma Active (positive) 13 Nov 2019
autologous CD4+ and CD8+ T cells expressing a CD19-specific chimeric antigen receptor (lisocabtagene maraleucel)
EU/3/18/2018
Treatment of follicular lymphoma Withdrawn 25 May 2018
Humanised Fc-engineered monoclonal antibody against CD19
EU/3/17/1962
Treatment of IgG4-related disease Active (positive) 17 Jan 2018
autologous CD4+ and CD8+ T cells expressing a CD19-specific chimeric antigen receptor (lisocabtagene maraleucel)
EU/3/17/1890
Treatment of diffuse large B-cell lymphoma Withdrawn 17 Jul 2017
autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19 (tisagenlecleucel)
EU/3/16/1745
Treatment of diffuse large B-cell lymphoma Active (positive) 14 Oct 2016
allogeneic donor-derived ex-vivo expanded T lymphocytes transduced with a retroviral vector containing inducible caspase 9 and truncated CD19
EU/3/16/1674
Treatment in haematopoietic stem cell transplantation Withdrawn 27 Jun 2016
autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor (axicabtagene ciloleucel)
EU/3/15/1579 · now authorised as Yescarta
Treatment of follicular lymphoma Active (positive) 11 Nov 2015
autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor (axicabtagene ciloleucel)
EU/3/15/1572
Treatment of chronic lymphocytic leukaemia / small lymphocytic lymphoma Withdrawn 11 Nov 2015
autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor (axicabtagene ciloleucel)
EU/3/15/1571
Treatment of acute lymphoblastic leukaemia Withdrawn 11 Nov 2015
autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor (axicabtagene ciloleucel)
EU/3/15/1553 · now authorised as Yescarta
Treatment of primary mediastinal large B-cell lymphoma Active (positive) 9 Oct 2015
autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor (axicabtagene ciloleucel)
EU/3/15/1552
Treatment of mantle cell lymphoma Withdrawn 9 Oct 2015
Humanised Fc engineered monoclonal antibody against CD19 (tafasitamab)
EU/3/14/1424 · now authorised as Minjuvi
Treatment of diffuse large B-cell lymphoma Active (positive) 15 Jan 2015
autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3 zeta chimeric antigen receptor (axicabtagene ciloleucel)
EU/3/14/1393 · now authorised as Yescarta
Treatment of diffuse large B-cell lymphoma Active (positive) 16 Dec 2014
Humanised Fc engineered monoclonal antibody against CD19 (tafasitamab)
EU/3/14/1286
Treatment of chronic lymphocytic leukaemia / small lymphocytic lymphoma Active (positive) 4 Jul 2014
autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19 (tisagenlecleucel)
EU/3/14/1266 · now authorised as Kymriah
Treatment of B-lymphoblastic leukaemia/lymphoma Active (positive) 29 Apr 2014
recombinant antibody derivative against human CD19 and CD3 (blinatumomab)
EU/3/03/176
Treatment of chronic lymphocytic leukaemia Withdrawn 1 Dec 2003
recombinant antibody derivative against human CD19 and CD3 (blinatumomab)
EU/3/03/175
Treatment of mantle cell lymphoma Withdrawn 1 Dec 2003

New orphan designations and approvals, weekly

One email every Friday: new EMA, FDA and Health Canada approvals, EU and US medicine shortages, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Every row is copied from the EMA's orphan designations data, reproduced with acknowledgement of the source. Each substance links to its official EMA page.

A daily job downloads the EMA's orphan designations JSON report and lists every designation, newest first. No AI drafting and no editorial pass. See our editorial standards. The the EMA data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.